Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Co. stock logo
CVS
CVS Health
$55.90
+1.4%
$72.77
$53.70
$83.25
$70.18B0.5612.50 million shs23.95 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$125.00
-0.5%
$105.05
$62.55
$142.79
$47.86B1.573.45 million shs4.51 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Co. stock logo
CVS
CVS Health
+1.35%-16.80%-25.09%-23.53%-20.24%
Moderna, Inc. stock logo
MRNA
Moderna
-0.47%+15.77%+23.51%+28.21%-3.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CVS Health Co. stock logo
CVS
CVS Health
5 of 5 stars
4.35.03.33.92.23.35.0
Moderna, Inc. stock logo
MRNA
Moderna
3.4327 of 5 stars
2.12.00.04.61.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVS Health Co. stock logo
CVS
CVS Health
2.63
Moderate Buy$80.3543.74% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.25
Hold$129.553.64% Upside

Current Analyst Ratings

Latest MRNA and CVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$91.00 ➝ $106.00
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $135.00
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $163.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $77.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$85.00 ➝ $74.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$78.00 ➝ $63.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $66.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $72.00
5/2/2024
CVS Health Co. stock logo
CVS
CVS Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$85.00 ➝ $60.00
5/2/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/1/2024
CVS Health Co. stock logo
CVS
CVS Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVS Health Co. stock logo
CVS
CVS Health
$357.78B0.20$12.31 per share4.54$59.07 per share0.95
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.99N/AN/A$33.47 per share3.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVS Health Co. stock logo
CVS
CVS Health
$8.34B$5.699.826.250.862.03%13.53%4.03%8/7/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$15.67N/AN/AN/A-115.82%-20.10%-15.00%8/1/2024 (Estimated)

Latest MRNA and CVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Moderna, Inc. stock logo
MRNA
Moderna
-$3.59-$3.07+$0.52-$3.07$93.26 million$167.00 million    
5/1/2024Q1 2024
CVS Health Co. stock logo
CVS
CVS Health
$1.69$1.31-$0.38$1.74$89.33 billion$88.44 billion      
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
2/7/202412/31/2023
CVS Health Co. stock logo
CVS
CVS Health
$2.01$2.12+$0.11$2.66$90.58 billion$93.81 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CVS Health Co. stock logo
CVS
CVS Health
$2.664.76%+6.56%46.75%2 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and CVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/21/2024
CVS Health Co. stock logo
CVS
CVS Health
quarterly$0.66503.39%4/19/20244/22/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVS Health Co. stock logo
CVS
CVS Health
0.78
0.81
0.63
Moderna, Inc. stock logo
MRNA
Moderna
0.04
4.03
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CVS Health Co. stock logo
CVS
CVS Health
80.66%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
CVS Health Co. stock logo
CVS
CVS Health
0.24%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CVS Health Co. stock logo
CVS
CVS Health
300,0001.26 billion1.26 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable

MRNA and CVS Headlines

SourceHeadline
Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 SharesModerna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares
insidertrades.com - May 4 at 7:32 AM
Moderna (NASDAQ:MRNA) Announces Quarterly  Earnings ResultsModerna (NASDAQ:MRNA) Announces Quarterly Earnings Results
marketbeat.com - May 3 at 11:54 PM
Canaccord Genuity Group Increases Moderna (NASDAQ:MRNA) Price Target to $106.00Canaccord Genuity Group Increases Moderna (NASDAQ:MRNA) Price Target to $106.00
marketbeat.com - May 3 at 10:16 PM
Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in StockModerna, Inc. (NASDAQ:MRNA) Director Sells $1,663,800.00 in Stock
marketbeat.com - May 3 at 8:16 PM
Modernas Loss in Q1 Was Less Than ExpectedModerna's Loss in Q1 Was Less Than Expected
fool.com - May 3 at 7:20 PM
Navigating 6 Analyst Ratings For ModernaNavigating 6 Analyst Ratings For Moderna
markets.businessinsider.com - May 3 at 7:20 PM
Shhh! 3 Secret Pharma Stocks Flying Below Wall Streets RadarShhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
investorplace.com - May 3 at 6:15 AM
MRNA Earnings: Moderna Reports Mixed Results in Q1MRNA Earnings: Moderna Reports Mixed Results in Q1
msn.com - May 3 at 12:26 AM
Moderna’s stock surges after better-than-expected quarterly resultsModerna’s stock surges after better-than-expected quarterly results
msn.com - May 3 at 12:26 AM
Why Moderna Stock Blasted 13% Higher TodayWhy Moderna Stock Blasted 13% Higher Today
fool.com - May 2 at 6:36 PM
Moderna (NASDAQ:MRNA) Stock Price Up 9.4%Moderna (NASDAQ:MRNA) Stock Price Up 9.4%
marketbeat.com - May 2 at 5:44 PM
Moderna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLCModerna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLC
marketbeat.com - May 2 at 2:39 PM
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after reviewModerna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
fiercebiotech.com - May 2 at 2:25 PM
Moderna gears up for potential RSV vaccine launch this fall after better-than-expected first quarterModerna gears up for potential RSV vaccine launch this fall after better-than-expected first quarter
fiercepharma.com - May 2 at 2:25 PM
Moderna (MRNA) Q1 2024 Earnings Call TranscriptModerna (MRNA) Q1 2024 Earnings Call Transcript
msn.com - May 2 at 2:25 PM
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock SoarsModerna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
msn.com - May 2 at 2:25 PM
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/YModerna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
zacks.com - May 2 at 12:16 PM
MRNA Stock Earnings: Moderna Beats EPS, Beats Revenue for Q1 2024MRNA Stock Earnings: Moderna Beats EPS, Beats Revenue for Q1 2024
investorplace.com - May 2 at 12:03 PM
Moderna, Inc. 2024 Q1 - Results - Earnings Call PresentationModerna, Inc. 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 2 at 11:19 AM
2 Biotech Stocks To Watch Today Amid Earnings2 Biotech Stocks To Watch Today Amid Earnings
stockmarket.com - May 2 at 10:18 AM
Moderna: Q1 Earnings SnapshotModerna: Q1 Earnings Snapshot
thehour.com - May 2 at 9:25 AM
Moderna Walks Away from Potential $3B Gene Editing Deal with MetagenomiModerna Walks Away from Potential $3B Gene Editing Deal with Metagenomi
biospace.com - May 2 at 9:25 AM
Moderna revenues plummeted after sales of its COVID-19 vaccine fell 91%Moderna revenues plummeted after sales of its COVID-19 vaccine fell 91%
msn.com - May 2 at 9:25 AM
Moderna tops forecasts in Q1 despite COVID-related sales slumpModerna tops forecasts in Q1 despite COVID-related sales slump
msn.com - May 2 at 9:25 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CVS Health logo

CVS Health

NYSE:CVS
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.